Employees want to know that their employers have a vested interest in their health, Vikki Walton, MBA, health equity leader at Mercer, explains.
Employers play an important role in health equity, and Vikki Walton, MBA, health equity leader at Mercer, explained how to improve that through a company’s diversity, equity, and inclusion (DE&I) strategy in a presentation at the Greater Philadelphia Business Coalition on Health (GPBCH).
Transcription
When you begin working with an employer, what are the key starting points to improving health equity?
We go in and we first have the conversation about education. So, we have to educate them. Again, a lot of times employers recognize that with health equity or social determinants of health, they might know a little bit about it, but not so much. So, we go in and we have to educate staff around exactly what it means. And then we go in and we start to assess their actual benefits. We go in and do a deep dive into what they're offering and then tie it to different groups of cohorts.
So, if we are looking at the LGBTQ+ community, what are they doing around gender-affirming care? If we're looking at women, reproductive health, what are we doing? What are we offering? How can we support that? What does travel and lodging look like for those who want to have care at centers of excellence? So we go in and we do a deep dive, which will take some time, to assess what they currently offer.
We also do data harvesting. What does your data look like? As we start to support your inclusive benefits, what are we seeing with populations? So we go in and look at that. We also look at social determinants of health, where we look at the social vulnerability index to identify are there populations that are experiencing access to care. How can we support that? So, we take a methodical approach to assessing their overarching benefit platform, and then from there, start to look at what those interventions might look like.
Are there any research areas of interest?
Yeah, so the question always comes up of, well, what's the return on investment? How can we identify whether we’re being effective if this is our approach? We have seen research with the AMA [American Medical Association] that has looked at employers’ role and how a healthy employee will support a healthy workforce, and the importance of that. We've had surveys from employees saying,“This is what we want and we’re interested in having employers take a vested interest in our health and specifically targeted groups.”
But we also look at utilization and employee engagement, and then overarching outcomes as we develop. So as far as research, it's kind of individualized depending on what the employer is looking to gain. And then over time, I believe we'll be able to harvest and have robust outcomes data to support when employers start to improve the access and be more strategic and intentional when it comes to certain cohorts.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More